Stock Analysis, Dividends, Split History

EML / Eastern Company financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price28.90
Volume6,400.00
Market Cap ($M)177.98
Enterprise Value ($M)194.45
Book Value ($M)92.52
Book Value / Share14.76
Price / Book1.92
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 6,263,245
Common Shares Outstanding 6,263,245
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.04
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Assets184.09
Liabilities91.56
Quick Ratio1.54
Current Ratio2.98
Income Statement (mra) ($M)
Sales Revenue Goods Net204,239,613.00
Operating Income12.28
Net Income5.05
Earnings Per Share Diluted0.80
Earnings Per Share Basic0.81
Cash Flow Statement (mra) ($M)
Cash From Operations11.18
Cash from Investing-42.80
Cash from Financing-42.80
Identifiers and Descriptors
CUSIP276317104
Central Index Key (CIK)31107

Split History

Stock splits are used by Eastern Company to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

16h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

The Eastern Company (EML) CEO August Vlak on Q2 2018 Results - Earnings Call Transcript

2018-08-11 seekingalpha
Good day, everyone, and welcome to the Eastern Company's Second Quarter 2018 Earnings Conference Call. Today's call is being recorded. (0-1)

MIDEAST STOCKS-SABIC beat fails to lift Saudi; Dubai, Abu Dhabi lower

2018-07-29 reuters
DUBAI, July 29 (Reuters) - Saudi Arabia’s stock market slid on Sunday as better-than-expected earnings from Saudi Basic Industries Corp (SABIC), the largest listed company in the Gulf, failed to lift investor sentiment.

The Eastern Company's (EML) CEO August Vlak on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Good morning, ladies and gentlemen and welcome to the First Quarter 2018 Earnings Call. My name is Simmy [ph] and I'm the event manager. [Operator Instructions] I would like to advise all parties, this conference is being recorded. (6-0)

AES Corp's (AES) CEO Andrés Weilert on Q1 2018 Results - Earnings Call Transcript

2018-05-08 seekingalpha
Good morning, and welcome to The AES Corporation's First Quarter 2018 Financial Review Conference Call. [Operator Instructions]. Please note, this event is being recorded. (41-0)

Can Permian Save SM Energy?

2018-04-06 seekingalpha
While SM Energy experienced overall production decline in 2017, its Permian operation is seeing a massive increase in production. (8-0)

CUSIP: 276317104